APVO
Aptevo Therapeutics IncNASDAQ
Healthcare • Biotechnology
$1.24-2.36%
Close Nov 6, 2026
- Market cap
- $2.24M
- 1 month
- -31.1%
- 3 months
- -69.2%
- 1 year
- -95.2%
- Dividend
- No dividends on record
- Short interest
- 5.7% of float96.5K shares · settled Oct 15, 2026 · -19.2% since Sep 30, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- —
- Net income
- -$26.41M
- Free cash flow
- -$25.34M
- Book value
- $6.04M
- Total debt
- $4.21M
- P/E
- —
- Price / sales
- —
- Price / book
- 0.4×
- FCF yield
- -1,129.0%
- Net margin
- —
EODHD (TTM) · as of Nov 6, 2026
End-of-day close from stored market data, not a live quote.
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States.
Read more
The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
- Website
- aptevotherapeutics.com
- Headquarters
- Seattle, WA, United States
- Employees
- 33
- Listed
- Jul 20, 2016
- Fiscal year ends
- December
Company profile from EODHD, stored Nov 2, 2026.
Quarterly results
The last 8 fiscal quarters as reported (EODHD). Year over year compares the same quarter a year earlier.
| Quarter | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Jun 2026filed Aug 14, 2026 | — | — | — | -$6.4M | -$6.4M |
| Mar 2026filed May 13, 2026 | — | — | — | -$6.8M | -$6.7M |
| Dec 2025filed Mar 26, 2026 | — | — | — | -$6.0M | -$5.8M |
| Sep 2025filed Nov 6, 2025 | — | — | — | -$7.6M | -$7.5M |
| Jun 2025filed Aug 11, 2025 | — | — | — | -$6.2M | -$6.2M |
| Mar 2025filed May 15, 2025 | — | — | — | -$6.5M | -$6.4M |
| Dec 2024filed Feb 14, 2025 | — | — | — | -$6.4M | -$6.3M |
| Sep 2024filed Nov 7, 2024 | — | — | — | -$5.2M | -$5.1M |
Fiscal years · last 6
| Fiscal year | Revenue | YoY | Gross margin | Op. income | Net income |
|---|---|---|---|---|---|
| Dec 2025filed Mar 26, 2026 | — | — | — | -$26.3M | -$26.0M |
| Dec 2024filed Feb 14, 2025 | — | — | — | -$24.6M | -$24.1M |
| Dec 2023filed Mar 5, 2024 | — | — | — | -$28.9M | -$17.4M |
| Dec 2022filed Mar 30, 2023 | $3.1M | -74.7% | — | -$28.6M | $8.0M |
| Dec 2021filed Mar 24, 2022 | $12.3M | +185.3% | — | -$21.4M | -$27.3M |
| Dec 2020filed Mar 31, 2021 | $4.3M | -86.7% | -314.3% | -$27.5M | -$17.8M |
Short-interest history
FINRA reports open short positions for a settlement date. The publication date is later. These are reported positions, with a separate date for each observation.
Compare the reported short exposure around the dates you bought, sold or watched APVO. A long position benefits from price rises; a short position benefits from falls. A change in these counts does not predict either move.
Settlement Oct 15, 2026
96,527 shares short
-22,930 shares (-19.2%) vs Sep 30, 2026
5.7% of the stored float. Published Oct 26, 2026.
Settlement Sep 30, 2026
119,457 shares short
-68,485 shares (-36.4%) vs Sep 15, 2026
7% of the stored float. Published Oct 9, 2026.
Settlement Sep 15, 2026
187,942 shares short
+69,754 shares (+59%) vs Aug 31, 2026
17.2% of the stored float. Published Sep 24, 2026.
Settlement Aug 31, 2026
118,188 shares short
+36,443 shares (+44.6%) vs Aug 14, 2026
Share of float unavailable. Published Sep 10, 2026.
Settlement Aug 14, 2026
81,745 shares short
-5,882 shares (-6.7%) vs Jul 31, 2026
Share of float unavailable. Published Aug 25, 2026.
Settlement Jul 31, 2026
87,627 shares short
-49,622 shares (-36.2%) vs Jul 15, 2026
Share of float unavailable. Published Aug 11, 2026.
Change = this settlement’s shares short − the previous recorded settlement’s shares short; percentage change divides by that earlier count. A zero earlier count has no percentage change. Split-spanning counts are left uncompared. Float percentages use the stored settlement observation, not today’s float.
Source: stored FINRA equity short-interest records, up to six settlements from the last 240 days. FINRA data and reporting dates · How to read short interest
Dividends and stock splits
See the recorded cash amounts and dates behind APVO’s income, and the splits that change its share count. Dates below are stored event records, not confirmation of a payment to your account.
Cash-dividend records
No qualified cash-dividend records are stored. This does not establish that the company pays no dividend.
Up to six Polygon cash-dividend events, including recorded ex-dates within the next 120 days. Amounts retain their recorded currency and decimal precision. Historical amounts are not restated to a common split basis, annualized, or converted to dollars.
For a long holding, compare the ex-date with when you held the shares and check the pay date against your broker’s cash history. Owning the stock today does not establish past entitlement. For a short holding, a dividend can create a payment obligation to the share lender.
Ex-dates and special dividend rules · Short-sale dividend obligations · Dividend data definitions
Split history
1 for 18 · reverse split
Effective Dec 30, 2025
Each 18 pre-split shares become 1 post-split share.
Source: EODHD
1 for 20 · reverse split
Effective May 27, 2025
Each 20 pre-split shares become 1 post-split share.
Source: EODHD
1 for 37 · reverse split
Effective Dec 4, 2024
Each 37 pre-split shares become 1 post-split share.
Source: EODHD
1 for 44 · reverse split
Effective Mar 6, 2024
Each 44 pre-split shares become 1 post-split share.
Source: EODHD
1 for 14 · reverse split
Effective Mar 27, 2020
Each 14 pre-split shares become 1 post-split share.
Source: EODHD
Up to six stored split dates through Nov 7, 2026. Equivalent vendor ratios are combined; conflicting ratios are left out. This history may be incomplete.
A split changes the share count and per-share price basis; it does not by itself add investment value. Put your holding’s earlier and later share counts on the same basis before comparing them. This applies to both long shares and shares owed on a short position.
How stock splits workPortfolio context
Sign in to see your position size
We’ll show you if APVO is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
Smart money context
Holder IQ: MEDIUM
2 smart-money holders: institutions with a high Holder IQ
Q4 2023, filed Aug 16, 2024
Note: 13F filings are reported up to 45 days after quarter-end.Insider context
Sentiment: unknown
No recent insider trades detected.
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Red flags: 1
Read the insider context evidence
What it means for you
Sign in to read your holdings or watchlist context. No personal position or direction is inferred.
What happened
No directional recent-activity label is available. This context label is separate from the scored insider signal read.
Why it can matter
A count of reported activity describes a sample, not purchase conviction, an insider’s intent or a future price move. Neutral is not an all-clear, and absent direction is not neutral evidence.
How we got this
The current context rule reads at most 50 nonduplicate issuer/share-class records filed in the last 90 days. It counts a bullish direction or purchase code P toward bullish, and a bearish direction or sale code S toward bearish. A side must exceed the opposite count by more than two to set its label; otherwise nonzero directional counts produce neutral. Calculation unavailable for this saved label: its counts, exact records, as-of time and rule version are not supplied here. Do not substitute the separate scored read’s different window or denominator.
Where the data comes from
Stored SEC Forms 3/4/5 insider-signal records, ordered by filing date with amendment duplicates excluded. Filing date is not transaction date. The last-trade line locates recent reported activity; it does not date or reconstruct the complete count.
Get the Full Analysis for APVO
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.